Compare AbbVie Inc (ABBV) vs Clear Secure Inc (YOU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Clear Secure Inc — how do they compare? AbbVie Inc trades at $253.03 (market cap $449.91B), while Clear Secure Inc trades at $54.95 (market cap $5.63B). The key difference: AbbVie Inc is far larger — about 79.9× Clear Secure Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | YOU | |
|---|---|---|
Market Cap | $449.91B | $5.63B |
Sector | Health | Technology |
52-Week High | $261.07 | $62.36 |
52-Week Low | $184.85 | $28.38 |
Enterprise Value | $513.38B | $4.94B |
Dividend Yield | 2.72% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Clear Secure (YOU) trades at $56.74, up 5.48% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated at P/E 45.39. Recent Q1 2026 earnings beat expectations, and the AWS partnership expansion signals growth potential. Analyst sentiment is mixed with 44% buy ratings and consensus target near current price.
Outlook remains positive given strong member growth and cash flow generation, but high valuation multiples and competitive pressures present risks. The stock's technical overbought condition near resistance at $58 suggests potential near-term consolidation before further upside. Institutional interest appears balanced with moderate net cash flow growth supporting expansion initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
